FEMASYS INC — Form 8-K
Filed November 2, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 28/100
What the filing says
Femasys appointed John Moorhead to its Board of Directors as a board designee tied to an August 2026 private placement. Moorhead brings 12 years at Unilever's Seventh Generation (rising to CMO) and recent experience at SBM Life Science. The appointment replaces Dr. Kenneth Eichenbaum, who was the designee for the November 2025 private placement; no financial terms of either placement are disclosed in this filing.
Why this rating
Board appointment is administrative; marketing expertise may help commercialization but is non-financial. No deal size disclosed relative to $29.9M market cap.
See more from November 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.